ARQT vs SYK
Arcutis Biotherapeutics, Inc. vs Stryker Corporation — AI-powered side-by-side comparison
ARQT
Arcutis Biotherapeutics, Inc.
70
Buy
VS
SYK
Stryker Corporation
59
Buy
| Metric | ARQT | SYK |
|---|
| AI Score |
70
|
59
|
| Price |
$25.10
|
$330.05
|
| P/E Ratio |
112.59×
|
33.98×
|
| ROE |
-8.5%
|
14.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
65.2%
|
| Debt / Equity |
0.52×
|
0.62×
|
| Dividend Yield |
0.0%
|
1.1%
|
| RSI (14) |
34.6
|
44.6
|
| Beta |
1.526
|
0.771
|
| Expected Upside |
+2.3%
|
+13.1%
|
AI Committee View
Current Innellis committee reasoning for ARQT versus SYK.
ARQT leads by 11 points.
ARQT scores 70/100 (Buy) versus SYK at 59/100 (Buy).
ARQT Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- News sentiment is positive (+0.80 across 5 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
SYK Committee View
60% agreement
5 analysts
Positive signals support the current rating — eps growing 27.7% yoy. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 27.7% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 35.2 is moderate-to-rich — Value
- Price-to-book of 6.0x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical